Harvard Pilgrim Weighing Prilosec Promotion In Face Of Less Expensive PPIs
Executive Summary
Harvard Pilgrim Health Care is weighing the benefits of promoting AstraZeneca's Prilosec (omeprazole) within the managed care organization's network in the face of near-term patent expiration and less costly proton pump inhibitors.
You may also be interested in...
Cholesterol Drugs May Be Good Candidates For Managed Care Pull Throughs
Cholesterol-lowering agents may be good candidates for managed care pull through programs following the recent change in National Cholesterol Education Program guidelines, participants at a recent workshop on pharmaceutical managed care marketing suggested.
Cholesterol Drugs May Be Good Candidates For Managed Care Pull Throughs
Cholesterol-lowering agents may be good candidates for managed care pull through programs following the recent change in National Cholesterol Education Program guidelines, participants at a recent workshop on pharmaceutical managed care marketing suggested.
Interchangeability Of COX-2s And NSAIDs Will Be First RxIntelligence Study
Therapeutic interchangeability between COX-2 inhibitors and NSAIDs will be among the first research projects for RxIntelligence.